Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.52 |
| ▸ | THRA | P10827 | 17/20 | 0.52 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381782 | 0.90 | THRB (0.66) | THRBTHRA | |
| SCHEMBL13044716 | 0.89 | THRA (0.59) | THRBTHRABTN3A1 | |
| SCHEMBL13044551 | 0.85 | THRB (0.59) | THRBTHRA | |
| SCHEMBL13044652 | 0.84 | THRB (0.66) | THRBTHRA | |
| SCHEMBL13044688 | 0.83 | THRB (0.67) | THRBTHRAALDH1A1 | |
| SCHEMBL21291350 | 0.83 | THRB (0.56) | THRBTHRA | |
| SCHEMBL13946979 | 0.81 | THRB (0.59) | THRBTHRA | |
| SCHEMBL21291333 | 0.79 | THRB (0.58) | THRBTHRA | |
| SCHEMBL13044614 | 0.78 | THRB (0.67) | THRBTHRA | |
| SCHEMBL21291190 | 0.77 | THRA (0.53) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202789-B2 | Method of treating glycogen storage disease | VIKING THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20190343850-A1 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE | VIKING THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202789-B2 | Method of treating glycogen storage disease | GYS2, GYS1, PYGL | THRB 7/4885THRA 9/4885BTN3A1 3792/4885 |
| US-20190343850-A1 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE | GYS2, GYS1, PYGL | THRB 7/4885THRA 9/4885BTN3A1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.